Return to NORVASC.com

NORVASC Safety Information:

NORVASC is indicated for high blood pressure and angina. In clinical trials, the most common side effects for NORVASC versus placebo were edema (8.3% vs 2.4%), headache (7.3% vs 7.8%), fatigue (4.5% vs 2.8%), and dizziness (3.2% vs 3.4%).

Caduet Safety Information:

Caduet is a prescription drug that combines two medicines, NORVASC^® (amlodipine besylate) and Lipitor^® (atorvastatin calcium). NORVASC is used to treat high blood pressure (hypertension), chest pain (angina), or blocked arteries of the heart (coronary artery disease); Lipitor is used along with diet and exercise to lower high cholesterol. It is also used to lower the risk of heart attack and stroke in people with multiple risk factors for heart disease - such as family history, high blood pressure, age, low HDL-C, or smoking.

Lipitor is also used in patients with type 2 diabetes and at least one other risk factor for heart disease such as high blood pressure, smoking or complications of diabetes, including eye disease and protein in urine, to reduce the risk of heart attack and stroke.

Caduet is not for everyone. It is not for those with liver problems. And it is not for women who are nursing, are pregnant, or may become pregnant. If you take Caduet, tell your doctor if you feel any new muscle pain or weakness. This could be a sign of rare but serious muscle side effects. Tell your doctor about all of the medicines you take. This may help avoid serious drug interactions. Your doctor should do blood tests to check your liver function before and during treatment and may adjust your dose. If you have any heart problems, be sure to tell your doctor. The most common side effects are edema, headache and dizziness. They tend to be mild and often go away.

Caduet is one of many options for treating high blood pressure and high cholesterol, in addition to diet and exercise, that you and your doctor can consider.

Click here for NORVASC prescribing information.

*	IMS Health National Prescription Audit, February 2006.